Eurofins Viracor LLC, a leader in testing for infectious disease, immunology, and allergy, is proud to announce the launch of a revolutionary test that can evaluate the effects of Chimeric Antigen Receptor T-Cell (CAR-T) therapy in pre-B cell acute lymphoblastic leukemia and B cell lymphomas patients. This novel test is part of the Eurofins network of companies and a groundbreaking development in the fight against cancer.
CAR-T therapy is revolutionizing the fight against cancer, offering a potential solution to even the most difficult-to-treat diseases. To help clinicians better understand how this revolutionary treatment is performing in their patients, Eurofins Viracor has developed a test that provides invaluable insights. The test is based on a method that has already yielded promising results in treating a variety of cancers, giving hope to those suffering from the disease.
CAR-T therapy is a powerful and promising form of treatment for many diseases. To ensure long-term success for this therapy, researchers are using a test to evaluate the CAR-T cell population in the patient’s body. This test provides an accurate and comprehensive assessment of the CAR-T cell population, giving clinicians important information to guide the effectiveness of the therapy. With this assessment, they can determine the persistence and expansion of the CAR-T cells, and gain insight into how long the therapy will remain effective for the patient.
The unveiling of this groundbreaking test promises to revolutionize the way we evaluate and treat cancer patients with CAR-T therapy. Clinicians now have a powerful tool to aid them in making the most informed decisions about their patient’s care. This is a major milestone in the fight against cancer and is sure to open up new possibilities for those affected.
About Eurofins– the global leader in bio-analysis
Eurofins is a global leader in Testing for Life, with 61,000 passionate staff in 940 laboratories across 59 countries, offering an expansive portfolio of over 200,000 analytical methods. With shares listed on the Euronext Paris Stock Exchange, Eurofins stands as a symbol of the potential of life-changing technology.